Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
Thermo Fisher Scientific
| Company | Thermo Fisher Scientific |
|---|---|
| Name of system | Ion Torrent Genexus Integrated Sequencer; Ion Torrent Genexus Dx Integrated Sequencer |
| City, State | Carlsbad, CA |
| Phone | 800-955-6288 |
| Website | |
| System application/FDA cleared or approved | Genexus: research use; Genexus Dx: in vitro diagnostic and research use/not required |
| Country where designed/Manufactured | U.S./Singapore |
| First year sold in U.S./First year installed in U.S. | Genexus: 2019/2019; Genexus Dx: 2025/2025 |
| System sold internationally | Genexus: yes (worldwide); Genexus Dx: yes (multiple countries) |
| Dimensions of sequencer (H × W × D)/Footprint of sequencer | open: 81.1 × 58.5 × 43.5 in.; closed: 66.1 × 41.9 × 32.1 in./open: 17.67 sq. ft.; closed: 9.36 sq. ft. |
| Accessory equipment supplied with sequencer at no cost | none |
| Type of computer supplied with sequencer | computer for analysis |
| Analysis options provided with sequencer | onboard, cloud based |
| Where library preparation is performed | sequencer |
| Bioinformatics tools provided with sequencer | Ion Torrent Genexus Software (optional: Oncomine Reporter) |
| Sequencer supplied with UPS (uninterruptible power supply) | no |
| Electrical connection required for sequencer | 100–240 VAC |
| List price of entire sequencer and necessary components | — |
| Purchase options | purchase, trade in, lease, reagent rental, finance |
| Warranties offered | first year included with purchase; extended warranty avail. |
| Training included/Total time for basic training per operator | yes/2 days |
| Training location/Follow-up training available | at customer site/yes (extra charge) |
| Maximum No. of samples amplified in a single amplification event | 48 samples on system, 96 samples off instr. (for library prep) |
| Read length/Percent bases >Q30 | up to 400 bp/— |
| Paired-end capability/Tag lengths/Spans | — |
| Fragment/Tag lengths/Spans | — |
| Mate pair/Tag lengths/Spans | — |
| Single end/Tag lengths/Spans | yes/—/up to 400 bp |
| RNA sequencing/Tag lengths/Spans | — |
| ChIP sequencing/Tag lengths/Spans | — |
| Bisulfite sequencing/Tag lengths/Spans | — |
| Maximum No. of reads or fragments sequenced per single-end run | 48–60 million at 200–400 bp (GX5, GX5 Dx); 80–100 million at 200 bp (GX7) |
| Maximum No. of reads or fragments sequenced per paired-end run | — |
| Total No. of nucleotides (bases) sequenced per run | 9.6–12 Gb at 200 bp (GX5, GX5 Dx); 16–20 Gb at 200 bp (GX7) |
| Wet lab bench time for sequencing preparation | 10 minutes |
| Sequencing run time | 19–24 hours (includes automated library prep) |
| Total time for generating standard gDNA library | — |
| • Paired end | — |
| • Fragment | — |
| • Mate pair | — |
| • Single end | — |
| • RNA sequencing | — |
| • Bisulfite sequencing | — |
| • Hands-on time for paired end | — |
| • Hands-on time for fragment | — |
| • Hands-on time for mate pair | — |
| • Hands-on time for single end | — |
| • Hands-on time for RNA sequencing | — |
| • Hands-on time for ChIP sequencing | — |
| • Hands-on time for bisulfite sequencing | — |
| Library preparation integrated in system as standard offering | yes (AmpliSeq, AmpliSeq HD) |
| Cost of sequencing reagents per run | — |
| Reagent tracking method | RFID, barcode reader |
| • Type of reagent information tracked | expiration date, lot and part Nos., placement |
| Shipping conditions for amplification/sequencing reagents | -20°C, 4°C, ambient (variable based on product)/-20°C, 4°C, ambient (variable based on product) |
| Storage conditions for amplification/sequencing reagents | -20°C, 4°C, ambient (variable based on product)/-20°C, 4°C, ambient (variable based on product) |
| Shelf life of amplification/sequencing reagents | 12–36 months from manufacture date (variable based on product)/12–36 months from manufacture date (variable based on product) |
| System requires a control sample on sequencing run | optional |
| • Company offers a sequencing control | yes (additional charge) |
| Sequencing system control software and devices to start run/for data analysis | Ion Torrent Genexus Software/Genexus Software, Oncomine Reporter |
| Complete walkaway automation for amplification, sequencing, and variant calling | yes |
| Remote system monitoring | yes |
| Total time required for setup of amplification, sequencing, and variant calling steps | 10 minutes |
| Maximum No. of libraries sequenced in a single run | 48 samples or 96 libraries |
| System includes secondary data-analysis software developed by company | yes (Ion Reporter, Oncomine Reporter) |
| System includes post-sequencing data-analysis software | yes (Genexus: Genexus Software, Oncomine Reporter;Genexus Dx: Genexus Dx Software, Oncomine Reporter) |
| Mutations detectable via data-analysis software | substitutions, indels, copy number changes, fusions |
| System can generate a variant report | yes |
| Types of maintenance plans available/mean time between failures | AB Assurance, AB Platinum NGS (Dx plans also avail.)/— |
| No. of field application scientists and engineers based in U.S. | 450 |
| • Weekly maintenance required | none |
| • Monthly maintenance required | none |
| • Pre-run maintenance required | none |
| Distinguishing features of NGS system (supplied by company) | Dx sequencer is a CE-IVD-marked, FDA-listed class II IVD medical device; walkaway automation of NGS workflow, incl. library prep, sequencing, analysis, reporting; start with as little as 1 ng of input DNA or RNA; scalable plug-and-play reagent architecture allows for cost-efficient sequencing of small and large batches |